References
- Australian Bureau of Statistics. Asthma. 2023;Dec. At: www.abs.gov.au/statistics/health/health-conditions-and-risks/asthma/latest-release
- Asthma Australia. Asthma burden in 2024. 2024;Dec. At: https://asthma.org.au/health-professionals/asthma-digest/asthma-burden-in-2024/
- Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Eng J Med 2018;378:1877–87. At: www.nejm.org/doi/full/10.1056/NEJMoa1715275
- National Asthma Council Australia. Australian asthma handbook. Version 2.2. Melbourne: NACA; 2023. At: www.asthmahandbook.org.au
- Medicines and Healthcare products Regulation Agency. Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines. 2025;Apr. At: www.gov.uk/drug-safety-update/short-acting-beta-2-agonists-saba-salbutamol-and-terbutaline-reminder-of-the-risks-from-overuse-in-asthma-and-to-be-aware-of-changes-in-the-saba-prescribing-guidelines
- Bateman ED, O’Byrne PM, FitzGerald JM, et al. Positioning as-needed budesonide-formoterol for mild asthma: effect of prestudy treatment in pooled analysis of SYGMA 1 and 2. Ann Am Thorac Soc 2021;18(12):2007–17. At: https://pmc.ncbi.nlm.nih.gov/articles/PMC8750058/
- Asthma Australia. Medicines. MART: maintenance and reliever therapy. 2024;Nov. At: asthma.org.au/medicines/mart-maintenance-and-reliever-therapy/
- National Asthma Council Australia. Breathing life into asthma management. 2025;Mar. At: www.nationalasthma.org.au/news/2025/breathing-life-into-asthma-management-18-march-2025
- Queensland Health. Prescribing scope of practice management: prescribing in community pharmacy. 2025;Jul. At: www.health.qld.gov.au/__data/assets/pdf_file/0031/1450984/guidance-prescribing-scope-practice.pdf
- Chandrasekara S, Wark P. Biologic therapies for severe asthma with persistent type 2 inflammation. Aust Prescr 2024;47:36–42. At: https://australianprescriber.tg.org.au/articles/biologic-therapies-for-severe-asthma-with-persistent-type-2-inflammation.html
- Asthma Australia. Spirometry. 2025. At: https://asthma.org.au/health-professionals/asthma-digest/spirometry/
- Asthma Australia. Medicines. Oral corticosteroids. 2025. At: https://asthma.org.au/medicines/oral-corticosteroids/
- Cleveland Clinic. Monoclonal antibodies. 202. At: https://my.clevelandclinic.org/health/treatments/22246-monoclonal-antibodies

Team PSA 2026: Caroline Diamantis FPS, Prof Mark Naunton MPS and Bridget Totterman MPS[/caption]
A/Prof Fei Sim and Prof Mark Naunton[/caption]

Clinical features
Warm compresses are the cornerstone of treatment, helping to soften the lesion, bring pus to the surface and encourage spontaneous drainage. A clean face cloth soaked in warm (not hot) water should be applied to the closed eyelid for 2–5 minutes, twice daily during the active phase. Once the stye begins to drain, any discharge should be gently wiped away using a clean, warm washcloth. After resolution, continuing warm compresses once daily may help prevent recurrence.2 






